Annual Report

Overview

The report says the Group recorded operating income of RMB12,629.58 million in 2022 and continued biologics and R&D development. It describes Board-level ESG oversight, environmental targets and TCFD-related review. It also reports a chronic-disease public-welfare program that helped more than 6,400 low-income patients.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Publication date: 30 March 2023
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Materiality

Assessment
Basis

Assurance

Level
Standard
Scope
Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services